Trial Profile
A Phase 1a/1b Study of SUN-101 in Subjects with Pancreatic Ductal Adenocarcinoma Previously Treated with Gemcitabine or FOLFIRINOX
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Ivospemin (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 28 May 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as per Australian New Zealand Clinical Trials Registry.
- 14 Sep 2013 New trial record